Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 20.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 452,497 shares of the biopharmaceutical company’s stock after buying an additional 78,145 shares during the quarter. Fisher Asset Management LLC owned about 0.68% of Celldex Therapeutics worth $11,435,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Jennison Associates LLC increased its stake in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after buying an additional 321,325 shares during the period. Values First Advisors Inc. increased its stake in Celldex Therapeutics by 20.0% in the 4th quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company’s stock valued at $733,000 after buying an additional 4,837 shares during the period. BNP Paribas Financial Markets increased its stake in Celldex Therapeutics by 293.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock valued at $958,000 after buying an additional 21,013 shares during the period. Bellevue Group AG increased its stake in Celldex Therapeutics by 3.4% in the 3rd quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after buying an additional 100,000 shares during the period. Finally, Intech Investment Management LLC acquired a new position in shares of Celldex Therapeutics during the 3rd quarter worth $871,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, UBS Group assumed coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.38.

Celldex Therapeutics Stock Down 5.9 %

Celldex Therapeutics stock opened at $19.35 on Tuesday. Celldex Therapeutics, Inc. has a 52 week low of $19.31 and a 52 week high of $53.18. The firm’s 50-day simple moving average is $23.75 and its 200 day simple moving average is $28.80. The firm has a market capitalization of $1.28 billion, a PE ratio of -7.53 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. On average, research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.